At @ year , the overall rate of survival was @ % ( @ % confidence interval -LSB- CI -RSB- , @ to @ ) in the nivolumab group , as compared with @ % ( @ % CI , @ to @ ) in the dacarbazine group ( hazard ratio for death , @ ; @ % CI , @ to @ ; P < @ ) .